Glaukos has been granted a patent for an antimicrobial treatment system featuring a wearable photoactivation device. This device targets infected eyes by applying a photosensitizer and delivering controlled photoactivating light, generating reactive oxygen species to combat microbial infections without causing significant biomechanical changes. GlobalData’s report on Glaukos gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Glaukos, Customized implants was a key innovation area identified from patents. Glaukos's grant share as of July 2024 was 41%. Grant share is based on the ratio of number of grants to total number of patents.
Wearable device for antimicrobial eye treatment using light
The granted patent US12070618B2 outlines a method for antimicrobial treatment specifically targeting eye infections caused by microbes. The process begins with identifying an infected eye, potentially indicating conditions such as keratitis. A photosensitizer is then applied to the eye, followed by the use of a photoactivation device designed to fit over the eye. This device includes a chamber, light sources for photoactivation, and an inlet for oxygen delivery. The method emphasizes modifying oxygen conditions within the chamber to optimize the antimicrobial effect of the activated photosensitizer, which generates reactive oxygen species. The illumination parameters, such as wavelength and intensity, are carefully controlled to ensure effective treatment without causing biomechanical changes to the eye.
Additionally, the patent describes various enhancements to the treatment method. These include the use of heating elements to adjust temperature within the chamber, which can further influence the activation of the photosensitizer and its antimicrobial efficacy. The method also allows for the application of permeability enhancers, such as non-ionic surfactants, to improve the penetration of the photosensitizer into the eye and its uptake by the microbes. Mechanical forces may also be applied to facilitate this penetration. Notably, riboflavin is mentioned as a potential photosensitizer, with ultraviolet light being specified as a suitable source for photoactivation. This comprehensive approach aims to provide an effective antimicrobial treatment for eye infections while minimizing adverse effects.
To know more about GlobalData’s detailed insights on Glaukos, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies across the world’s largest industries.
